Logo image of RMTI

ROCKWELL MEDICAL INC (RMTI) Stock Fundamental Analysis

NASDAQ:RMTI - Nasdaq - US7743743004 - Common Stock - Currency: USD

1.77  -0.03 (-1.67%)

After market: 1.8 +0.03 (+1.69%)

Fundamental Rating

4

Overall RMTI gets a fundamental rating of 4 out of 10. We evaluated RMTI against 189 industry peers in the Health Care Equipment & Supplies industry. RMTI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, RMTI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

RMTI had negative earnings in the past year.
In the past year RMTI had a positive cash flow from operations.
In the past 5 years RMTI always reported negative net income.
RMTI had a negative operating cash flow in each of the past 5 years.
RMTI Yearly Net Income VS EBIT VS OCF VS FCFRMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of RMTI (-2.17%) is better than 67.02% of its industry peers.
The Return On Equity of RMTI (-4.24%) is better than 68.62% of its industry peers.
RMTI has a better Return On Invested Capital (1.06%) than 67.02% of its industry peers.
Industry RankSector Rank
ROA -2.17%
ROE -4.24%
ROIC 1.06%
ROA(3y)-41.16%
ROA(5y)-48.05%
ROE(3y)-486.08%
ROE(5y)-343.32%
ROIC(3y)N/A
ROIC(5y)N/A
RMTI Yearly ROA, ROE, ROICRMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

The Operating Margin of RMTI (0.59%) is better than 66.49% of its industry peers.
The Gross Margin of RMTI (16.91%) is worse than 80.85% of its industry peers.
RMTI's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.59%
PM (TTM) N/A
GM 16.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y33.36%
GM growth 5YN/A
RMTI Yearly Profit, Operating, Gross MarginsRMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RMTI is destroying value.
RMTI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RMTI has more shares outstanding
RMTI has a better debt/assets ratio than last year.
RMTI Yearly Shares OutstandingRMTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
RMTI Yearly Total Debt VS Total AssetsRMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

RMTI has an Altman-Z score of -6.32. This is a bad value and indicates that RMTI is not financially healthy and even has some risk of bankruptcy.
RMTI has a Altman-Z score of -6.32. This is in the lower half of the industry: RMTI underperforms 73.94% of its industry peers.
RMTI has a debt to FCF ratio of 3.99. This is a good value and a sign of high solvency as RMTI would need 3.99 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.99, RMTI belongs to the top of the industry, outperforming 83.51% of the companies in the same industry.
A Debt/Equity ratio of 0.34 indicates that RMTI is not too dependend on debt financing.
RMTI's Debt to Equity ratio of 0.34 is in line compared to the rest of the industry. RMTI outperforms 46.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.99
Altman-Z -6.32
ROIC/WACC0.11
WACC9.57%
RMTI Yearly LT Debt VS Equity VS FCFRMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

RMTI has a Current Ratio of 2.41. This indicates that RMTI is financially healthy and has no problem in meeting its short term obligations.
RMTI's Current ratio of 2.41 is in line compared to the rest of the industry. RMTI outperforms 43.09% of its industry peers.
RMTI has a Quick Ratio of 2.00. This is a normal value and indicates that RMTI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of RMTI (2.00) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2
RMTI Yearly Current Assets VS Current LiabilitesRMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.73% over the past year.
Looking at the last year, RMTI shows a very strong growth in Revenue. The Revenue has grown by 22.38%.
The Revenue has been growing slightly by 5.69% on average over the past years.
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%171.43%
Revenue 1Y (TTM)22.38%
Revenue growth 3Y10.36%
Revenue growth 5Y5.69%
Sales Q2Q%19.12%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
RMTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.20% yearly.
EPS Next Y106.37%
EPS Next 2Y36.37%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year19.4%
Revenue Next 2Y-0.57%
Revenue Next 3Y2.48%
Revenue Next 5Y15.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RMTI Yearly Revenue VS EstimatesRMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RMTI Yearly EPS VS EstimatesRMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -2 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RMTI. In the last year negative earnings were reported.
Also next year RMTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RMTI Price Earnings VS Forward Price EarningsRMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RMTI is valued cheaper than 82.45% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, RMTI is valued cheaply inside the industry as 87.77% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.71
EV/EBITDA 15.56
RMTI Per share dataRMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as RMTI's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.37%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

RMTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKWELL MEDICAL INC

NASDAQ:RMTI (2/21/2025, 8:00:01 PM)

After market: 1.8 +0.03 (+1.69%)

1.77

-0.03 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners25.7%
Inst Owner Change-81.98%
Ins Owners2.06%
Ins Owner Change-0.13%
Market Cap57.21M
Analysts82.5
Price Target6.63 (274.58%)
Short Float %1.79%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)257.7%
Min EPS beat(2)125.21%
Max EPS beat(2)390.2%
EPS beat(4)3
Avg EPS beat(4)124.58%
Min EPS beat(4)-47.06%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)72.03%
EPS beat(12)10
Avg EPS beat(12)61.29%
EPS beat(16)11
Avg EPS beat(16)45.6%
Revenue beat(2)2
Avg Revenue beat(2)7.63%
Min Revenue beat(2)4.77%
Max Revenue beat(2)10.49%
Revenue beat(4)3
Avg Revenue beat(4)3.35%
Min Revenue beat(4)-4.31%
Max Revenue beat(4)10.49%
Revenue beat(8)6
Avg Revenue beat(8)3.8%
Revenue beat(12)7
Avg Revenue beat(12)0.27%
Revenue beat(16)7
Avg Revenue beat(16)-2.93%
PT rev (1m)0%
PT rev (3m)-13.33%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)183.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF 21.71
P/OCF 17.37
P/B 1.96
P/tB 3.2
EV/EBITDA 15.56
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)0.08
FCFY4.61%
OCF(TTM)0.1
OCFY5.76%
SpS3.06
BVpS0.9
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.17%
ROE -4.24%
ROCE 1.35%
ROIC 1.06%
ROICexc 1.83%
ROICexgc 3.31%
OM 0.59%
PM (TTM) N/A
GM 16.91%
FCFM 2.66%
ROA(3y)-41.16%
ROA(5y)-48.05%
ROE(3y)-486.08%
ROE(5y)-343.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y33.36%
GM growth 5YN/A
F-Score6
Asset Turnover1.73
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.99
Debt/EBITDA 3.59
Cap/Depr 30.13%
Cap/Sales 0.67%
Interest Coverage 0.63
Cash Conversion 119.05%
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2
Altman-Z -6.32
F-Score6
WACC9.57%
ROIC/WACC0.11
Cap/Depr(3y)333.86%
Cap/Depr(5y)240.55%
Cap/Sales(3y)5.45%
Cap/Sales(5y)3.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%171.43%
EPS Next Y106.37%
EPS Next 2Y36.37%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)22.38%
Revenue growth 3Y10.36%
Revenue growth 5Y5.69%
Sales Q2Q%19.12%
Revenue Next Year19.4%
Revenue Next 2Y-0.57%
Revenue Next 3Y2.48%
Revenue Next 5Y15.2%
EBIT growth 1Y107.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.09%
EBIT Next 3Y35.92%
EBIT Next 5YN/A
FCF growth 1Y110.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.75%
OCF growth 3YN/A
OCF growth 5YN/A